At what enterprise value was POINT VISION acquired in 2021?

During the acquisition of POINT VISION by ARES / BPIFRANCE in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of POINT VISION when it was acquired by ARES / BPIFRANCE?

The estimated EV/EBITDA multiple for POINT VISION is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was POINT VISION acquired by ARES / BPIFRANCE?

POINT VISION was acquired by ARES / BPIFRANCE in 2021.

What was the revenue of POINT VISION at the time of the deal?

The revenue of POINT VISION at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of POINT VISION during the acquisition?

POINT VISION's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the POINT VISION acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the POINT VISION deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/ares-et-bpifrance-succedent-a-abenex-chez-point-vision-1354679

← DATABASE

Home Database Healthcare & PharmaPOINT VISION

10/2021

POINT VISION acquired by ARES & BPIFRANCE

FRANCE Health Providers / Outpatient Care / Ophthalmology EV 300M - 700M EUR

Context

Ares Management acquired a majority stake in Point Vision following a highly competitive auction process (beating Adagia, Ramsay, and Elsan). Bpifrance joined as a minority shareholder alongside Ares and the three founders who reinvested. Abenex, which entered in 2014 and held the majority since 2019, fully exited. The financing was secured through a unitranche facility provided by Tikehau Capital. The strategy focuses on expanding territorial coverage (especially in Auvergne-Rhone-Alpes and Ile-de-France) and digitizing the patient journey.

POINT VISION, which reported an EBITDA margin of LOGIN in 2021, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Point Vision is the leading operator of ophthalmology centers in France. Founded in 2012 by Dr. François Pelen, Patrice Pouts, and Raphael Schnitzer, the group was created to address a critical structural issue in the French healthcare system: the extreme shortage of ophthalmologists and the resulting excessive waiting times for appointments (often 3 to 6 months).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Other operations with POINT VISION

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
01/2026	POINT VISION	CLINIQUE DE LA VISION (REFRACT SAS)	FRANCE	Health Providers	Point Vision acquired a controlling stake in Refract SAS, the parent company of Clinique de la Vision. This acquisition allows Point Vision to integrate a leading refractive surgery capability into its vast consultation network. The target retains its identity and organization, but a medical advisory committee will be established to harmonize governance. This build-up follows the roadmap set by Ares Management (majority owner since 2021) to expand the group's medical offering.

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of POINT VISION by ARES / BPIFRANCE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: point vision

Acquirer: ares / bpifrance